 |
|
||||||||||||||||||
Antibody Monotherapy
In addition to Oregovomab, Quest has a portifolio of antibodies against other cancer antigens such as:
- MAb against MUC1
- MAb against TAG-72
- MAB against PSA
- MAb against CA19.9
The clinical relevance of these cancer antigens are depicted in the following table:
Antigen Disease |
MUC1 |
CA125 |
TAG72 |
CA19.9 |
PSA |
Ovarian |
65% |
97% |
53% |
- |
- |
Breast |
95% |
14% |
27% |
- |
- |
Lung |
70% |
33% |
52% |
- |
- |
Multiple Myeloma |
100% |
- |
- |
- |
- |
Pancreas |
100% |
67% |
38% |
92% |
- |
Stomach |
65% |
- |
55% |
60% |
- |
Colorectal |
- |
- |
67% |
58% |
- |
Prostate |
Recent literature suggests important Role
|
- |
- |
85% |
Anti-MUC-1 Antibody Therapy
- Completed Phase I Clinical Trial
- Evidence for the activation of humoral and cellular antitumor immunity
Phase I trial of murine antibody to MUC1 in patients with metastatic cancer (n=17) |
|
Antibody |
response |
HAMA (human anti-mouse antibodies) |
5 |
Ab2 (anti-idiotypic antibodies) |
5 |
Anti-MUC1 (mAb-AR20.5) |
5 |
DeBobo et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral
and cellular antitumor immunity. Ann Oncol 2004 Dec;15(12):1825-33.
